- EpilepsyGTx y Viralgen colaboran para impulsar un programa de terapia génica con vectores AAV para la epilepsia antes del ensayo inicial en humanos

La colaboración con una CDMO especializada en AAV respaldará la producción escalable de EPY201 para la epilepsia focal refractaria, que afecta a 10 millones de personas.

LONDRES y SAN SEBASTIÁN, España, 9 de septiembre de 2026 /PRNewswire/ -- EpilepsyGTx, una empresa de biotecnología que desarrolla terapias génicas para la epilepsia refractaria, y Viralgen, una organización líder de desarrollo y fabricación por contrato (CDMO) especializada en terapias génicas basadas en virus adenoasociados (AAV) recombinantes, han anunciado hoy una colaboración para apoyar la producción de EPY201 —el principal programa de terapia génica en fase de investigación de EpilepsyGTx dirigido a pacientes con epilepsia focal refractaria (FRE)— antes de la realización de los primeros ensayos clínicos en humanos.

Como parte de la colaboración, Viralgen utilizará su plataforma de fabricación patentada Aava™ para ofrecer una solución fiable y eficiente para la producción de EPY201. La plataforma permite una fabricación escalable y de alto rendimiento para diversos serotipos de AAV, y ya ha respaldado la producción de 1.500 lotes de AAV.

La epilepsia focal describe un grupo de trastornos en los que las crisis se originan en una parte específica del cerebro. Cuando las crisis persisten tras haber probado al menos dos fármacos antiepilépticos bien tolerados y seleccionados adecuadamente, la epilepsia se considera refractaria o farmacorresistente. La epilepsia focal refractaria afecta a aproximadamente 10 millones de pacientes en todo el mundo, incluidos dos millones en Estados Unidos, el Reino Unido y la Unión Europea.

EPY201 está diseñado para administrarse directamente en el foco epiléptico, con el objetivo de reducir la hiperexcitabilidad neuronal a nivel local y limitar la exposición fuera de la región cerebral diana. De tener éxito, este enfoque ofrecerá a los pacientes una opción única y mínimamente invasiva que no requiere resección ni ablación de tejido cerebral, brindando a los pacientes con epilepsia resistente a fármacos (FRE) la perspectiva de quedar libres de crisis.

Nicolas Koebel, consejero delegado de EpilepsyGTx, comentó: "La experiencia de Viralgen en la fabricación de vectores AAV y su plataforma, diseñada para respaldar programas desde las fases iniciales de desarrollo hasta la escala comercial, serán fundamentales a medida que nos preparamos para avanzar con EPY201 hacia el desarrollo clínico. La infraestructura, los conocimientos técnicos y la trayectoria regulatoria de Viralgen la convierten en un socio de fabricación excelente mientras trabajamos para acercar nuestro innovador enfoque de terapia génica a la práctica clínica".

Jimmy Vanhove, consejero delegado de Viralgen, declaró: "Nos enorgullece asociarnos con EpilepsyGTx en este importante programa. Nuestra plataforma Aava ha sido diseñada específicamente para escalar programas de AAV de manera eficiente, y nuestra experiencia en fabricación nos sitúa en una posición ideal para ayudar a EpilepsyGTx a hacer avanzar el EPY201 hacia los pacientes con epilepsia focal refractaria con la mayor rapidez posible".

Acerca de EpilepsyGTx

EpilepsyGTx es una empresa de biotecnología que desarrolla terapias génicas de vanguardia para la epilepsia. Su tecnología ofrece a los pacientes con epilepsia focal refractaria (FRE) la posibilidad de librarse de las crisis mediante un único procedimiento, administrado directamente en el foco epiléptico con un daño mínimo al tejido cerebral circundante.

La empresa ha generado pruebas sustanciales de una posible actividad anticonvulsiva y de tolerabilidad en modelos preclínicos traslacionales de FRE que abarcan diversas localizaciones del foco epiléptico. El programa principal de la empresa, EPY201, se administra en el foco epiléptico mediante administración intraparenquimatosa, lo que reduce la actividad neuronal y previene las convulsiones. EPY201 iniciará ensayos clínicos de fase inicial en humanos para la FRE en el primer semestre de 2027.

EpilepsyGTx se fundó en 2021 a partir de investigaciones pioneras del Instituto de Neurología del University College London, y sus fundadores aportan una dilatada y singular experiencia en investigación sináptica. Para más información, visite: www.epilepsygtx.com.

Acerca de EPY201

EPY201 es una terapia génica en fase de investigación dirigida a la epilepsia focal refractaria. EPY201, también conocido como AAV9-CAMK2A-EKC, utiliza una cápside AAV9, un promotor CAMK2A y una forma modificada de origen natural del canal de potasio Kv1.1 (denominada "EKC"). La terapia se administra directamente en el foco epiléptico diana —la región específica del cerebro responsable de las crisis— mediante administración intraparenquimatosa.

Acerca de Viralgen

Viralgen es una organización líder de desarrollo y fabricación por contrato (CDMO) especializada exclusivamente en terapias celulares y génicas basadas en virus adenoasociados (AAV). Fundada en 2017 como filial de AskBio Inc., dentro del grupo Bayer AG, Viralgen ofrece un servicio integral que abarca desde las fases iniciales de desarrollo hasta la fabricación comercial a gran escala. Gracias a su línea celular en suspensión patentada Pro10™ y a su plataforma de fabricación Aava™, Viralgen logra una producción escalable y de alto rendimiento —líder en el sector— para todos los serotipos de AAV.

Ubicada en San Sebastián (España), su instalación de vanguardia cuenta con tres salas cGMP con una capacidad de 2.000 litros cada una, certificadas por la AEMPS/EMA, e integra servicios que incluyen la producción de plásmidos, la optimización de procesos, el llenado y acabado y pruebas de control de calidad internas. Con más de 1.500 lotes de AAV producidos, Viralgen ofrece soluciones fiables y eficientes para llevar terapias génicas transformadoras a los pacientes con mayor rapidez y consistencia. Obtenga más información en viralgen.com y síganos en LinkedIn.

Share this article

HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit

HCB101 represents the first known U.S. Expanded Access case for a SIRPα Fc fusion protein enabling continued therapy beyond the parent study.

TAIPEI and SHANGHAI and SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its HCB101 Single-Patient Expanded Access Protocol (HCB101- EA-001) as "safe to proceed".

The FDA determination enables a patient who experienced clinical benefit while receiving HCB101 in the Company's Phase 1 study to continue treatment with HCB101 beyond the parent clinical trial. Expanded Access, or compassionate use, allows patients with serious or life-threatening diseases to receive investigational therapies outside standard clinical trials when specific regulatory criteria are met. In an individual-patient Expanded Access request, FDA considers the patient's clinical circumstances, including whether the potential benefit justifies the potential risks and whether those risks are reasonable in the context of the disease.

"For us, this starts with the patient," said Scott Liu, Ph.D., Founder and Chairman of HanchorBio. "When a patient is benefiting from an investigational therapy and has limited treatment options, we believe every appropriate avenue to continue access should be considered. HCB101 was created to make a meaningful difference, and this milestone reflects the patient-first principle guiding our FBDB™ platform."

FDA's determination that HCB101-EA-001 is "safe to proceed" applies specifically to this individual-patient Expanded Access protocol and does not constitute approval of HCB101 or an FDA determination of efficacy.

"Working within the FDA framework, we translated an individual patient's need into a practical solution allowing treatment to continue," said Alvin Luk, Ph.D., M.B.A., President and Chief Medical Officer (Group) and Chief Executive Officer (USA) of HanchorBio. "That is where clinical medicine, regulatory science, and drug development properly align."

A Potential First for the SIRPα-Fc Fusion Protein Class

While Expanded Access pathways have previously been utilized for the anti-CD47 monoclonal antibody, HCB101-EA-001 is clinically and structurally distinct:

Targeted Continuation: Unlike broad population access programs, HCB101-EA-001 was specifically established to extend treatment for an individual patient who determined clinical benefit during a Phase 1 clinical trial.

Novel Mechanism: HCB101 is an engineered SIRPα-Fc fusion protein designed to block the CD47-SIRPα "don't eat me" signal and trigger macrophage-mediated tumor-cell phagocytosis.

Based on publicly available information, HanchorBio believes this is the first reported U.S. Expanded Access case for a SIRPα-Fc fusion protein, setting a significant precedent as HanchorBio continues to advance the program globally across multiple tumor types and combination strategies.

About HCB101

HCB101 is an investigational engineered SIRPα–IgG4 Fc fusion protein developed using HanchorBio's FBDB™ platform. HCB101 blocks CD47–SIRPα signaling to restore macrophage-mediated antitumor immunity and downstream de novo T-cell activation. It is being evaluated as monotherapy (NCT05892718) and in combination (NCT06771622) across solid and hematologic malignancies and holds U.S. FDA Orphan Drug Designation for gastric cancer.

About HanchorBio

HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company focused on inventing next-generation biologics for cancer and immune-mediated diseases using its proprietary FBDB™ platform. HanchorBio's pipeline includes clinical-stage programs HCB101 and HCB301, next-generation trispecific program HCB303, and additional candidates across oncology and immune-mediated diseases.

Learn more at http://hanchorBio.com

Forward-Looking Statements

This press release contains forward-looking statements regarding HCB101, including its clinical development, potential therapeutic benefits, regulatory interactions, and the significance of the HCB101-EA-001 Expanded Access protocol. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

HCB101 is investigational and has not been approved for commercial use by the U.S. FDA or any other regulatory authority. FDA's determination that HCB101-EA-001 is "safe to proceed" applies only to this specific Expanded Access protocol and does not constitute approval of HCB101 or a determination of its safety or efficacy for a broader patient population.

HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.

SOURCE HanchorBio Inc.

Share this article

- Global Phase 3 trial will evaluate the darovasertib and crizotinib combination in primary uveal melanoma patients with increased risk of metastasis following completion of local therapy

- OptimUM-11 expands development of darovasertib across the uveal melanoma patient journey into the adjuvant setting, where there is a significant unmet need for systemic treatment options designed to reduce the risk of metastatic recurrence

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Servier, an independent international pharmaceutical group governed by a foundation, today announced that the first patient has been dosed in OptimUM-11, a global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C (PKC) inhibitor, in combination with crizotinib, an oral cMET inhibitor, as adjuvant therapy for patients with primary uveal melanoma who have completed local therapy and have an increased risk of developing metastatic disease. Currently, there are no approved adjuvant treatment options for patients with primary uveal melanoma.

"Dosing the first patient in OptimUM-11 represents an important milestone in our strategy to advance darovasertib across the uveal melanoma patient journey," said Darrin M. Beaupre, M.D., Ph.D., Chief Medical Officer of IDEAYA Biosciences. "Patients with primary uveal melanoma are commonly at risk for metastatic recurrence following treatment of their primary tumor, highlighting the need for an effective systemic therapy in the adjuvant setting to delay or prevent disease progression. We believe the darovasertib combination has the potential to address the principal pathways associated with the initiation and metastatic progression of uveal melanoma, and we look forward to working with our partner Servier and the global investigator community to advance this registrational trial."

"Preventing or delaying metastatic recurrence could fundamentally change the treatment journey for patients with high-risk primary uveal melanoma," said Arnaud Lallouette, Executive Vice President Global Medical & Patient Affairs at Servier. "Through OptimUM-11, Servier and IDEAYA are jointly advancing a global registrational study of the darovasertib combination with the goal of establishing a new adjuvant treatment option for patients worldwide."

OptimUM-11 is being conducted by IDEAYA in collaboration with its partner, Servier, to evaluate darovasertib in combination with crizotinib as an adjuvant therapy for patients with primary uveal melanoma. The trial is expected to enroll approximately 450 patients who have completed primary local therapy and have an increased risk of metastasis. Patients will be eligible irrespective of HLA status and will be randomized 1:1 to receive darovasertib in combination with crizotinib for 12 months or observation. The primary endpoint of the trial is relapse-free survival. IDEAYA retains regulatory and commercial rights to darovasertib in the United States, while Servier holds all such rights outside the United States. The companies will share the associated development costs of the trial.

About Darovasertib

Darovasertib is a potential first-in-class oral, small-molecule inhibitor of PKC. Darovasertib was designed to inhibit PKC isoforms downstream of the GNAQ and GNA11 oncogenic driver mutations that are present in nearly all uveal melanoma patients. Darovasertib is being evaluated in multiple clinical trials in uveal melanoma, including in patients with metastatic disease (OptimUM-01 and OptimUM-02), as well as in primary uveal melanoma as a neoadjuvant (OptimUM-09 and OptimUM-10) and adjuvant (OptimUM-11) therapy.

IDEAYA has initiated submission of a new drug application (NDA) for darovasertib in combination with crizotinib for patients with first line metastatic uveal melanoma (mUM) under the oncology center of excellence (OCE) real-time oncology review (RTOR) program and expects to complete the NDA submission in the second half of 2026. The U.S. Food and Drug Administration (FDA) has also granted darovasertib Fast Track designation for the treatment of mUM, Orphan Drug designation in primary uveal melanoma and Breakthrough Therapy Designation as a neoadjuvant therapy for patients with primary uveal melanoma for whom enucleation has been recommended. Darovasertib is an investigational product and has not been approved by the FDA or any other regulatory authority.

About Uveal Melanoma

Uveal melanoma is a rare and aggressive cancer arising from melanocytes in the eye and is biologically distinct from cutaneous melanoma. An estimated 10,000-12,000 new cases of primary uveal melanoma are diagnosed globally per year, including more than 3,000 new cases annually in the United States. Primary uveal melanoma is generally treated with local therapy, including plaque brachytherapy, radiation or surgical removal of the eye (enucleation). Despite effective control of the primary tumor, up to 50% of primary uveal melanoma patients eventually progress to metastatic disease. There remains a significant unmet need for systemic therapies capable of delaying or preventing metastatic disease progression following treatment of primary uveal melanoma.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small-molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer.

About Servier

Servier is an independent international pharmaceutical group governed by a foundation. With its governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. The Group intends to offer targeted therapeutic solutions, particularly in rare cancers and neurological diseases, and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. More information on the Group website: servier.com Follow us on social media: LinkedIn, Facebook, X, Instagram

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the design, conduct, enrollment, timing, progress, completion and results of the OptimUM-11 clinical trial; the potential safety, efficacy, tolerability and therapeutic benefits of darovasertib in combination with crizotinib; the potential for the darovasertib combination to improve relapse-free survival or delay or prevent metastatic recurrence in patients with primary uveal melanoma; the potential of darovasertib to become an important treatment option across the uveal melanoma patient journey; the timing, progress and outcome of regulatory activities; and the performance, expected activities and potential benefits of IDEAYA's collaboration with Servier. Such forward-looking statements are based on IDEAYA's management's current expectations, assumptions and beliefs and involve risks, uncertainties, and other factors that could cause actual results, including those related to IDEAYA's clinical programs, regulatory activities, commercial activities and performance or achievements, to differ significantly or materially from those expressed or implied by the forward-looking statements.

Such risks and uncertainties include, among others, risks relating to the timing, design, initiation, conduct and completion of clinical trials; the ability to activate clinical trial sites and enroll, retain and dose patients; the possibility that clinical trial results may not demonstrate the safety, tolerability, efficacy or therapeutic benefits anticipated by IDEAYA; the possibility that results from OptimUM-11 may not support regulatory submissions or approvals; the timing and outcome of interactions with the FDA and other regulatory authorities; uncertainties regarding the regulatory review process, including participation in the RTOR program; the ability to obtain and maintain regulatory approvals; manufacturing and drug-supply risks; reliance on clinical investigators, contract research organizations, manufacturers, suppliers and collaboration partners, including Servier; the ability of IDEAYA and Servier to perform their respective obligations and realize the anticipated benefits of their collaboration; competition and changes in the standard of care; the ability to successfully develop and commercialize product candidates; IDEAYA's ability to establish, protect and defend its intellectual property; and other matters that could affect the sufficiency of financial resources to fund operations.

The multi-year partnership kicks off with a new campaign starring New York Giants running back Cam

Skattebo and his senior rescue dog, Duke

NEW YORK, Sept. 9, 2026 /PRNewswire/ -- The Farmer's Dog®, the leader in real, human-grade dog food, today announced a landmark, multi-year partnership with the National Football League (NFL), becoming the league's first-ever Official Pet Food Partner. The agreement brings The Farmer's Dog and its mission to one of the most influential cultural platforms in America, introducing millions more dog owners to the power of real food.

From players and their families to fans across the country, dogs are by our side through so much of life. They're part of the traditions that make game day special, there through big wins, tough losses, and all the moments in between. The partnership will shine a light on that bond and celebrate the special place dogs hold in the lives of people who love the game.

"The NFL is all about bringing people together through shared experiences and community," said Tracie Rodburg, senior vice president of global partnerships at the NFL. "Dogs are an important part of many families, and as the Official Pet Food Partner, The Farmer's Dog will help us celebrate the role they play in our lives and communities throughout the season."

Throughout the year, fans can expect exclusive content, experiences at some of the NFL's biggest moments—including Super Bowl LXI, the NFL Combine, and the NFL Draft—and community initiatives through programs like My Cause My Cleats, NFL Salute to Service, NFL FLAG, and more.

The partnership launches with New York Giants running back Cam Skattebo and his senior rescue dog, Duke, longtime customers of The Farmer's Dog whose bond embodies the campaign's message. The spot follows them through the moments fans rarely see—the early mornings, long drives, recoveries, and routines that shaped both of them long before the NFL. It also features his Dachshund puppies, Cheech and Daizy, celebrating the joy dogs bring at every stage of life.

"I've had Duke for every high and every low. He's been my teammate long before football became my career. I started feeding him The Farmer's Dog because I wanted as many healthy years with him as possible," said Skattebo. "If The Farmer's Dog teaming up with the NFL gets even one more person thinking differently about what they feed their dog, that's something I'm proud to be part of."

The NFL and Skattebo join a growing roster of partners—including The Oprah Podcast®, NASCAR Champion Ryan Blaney, and No. 1 U.S. women's tennis player Jess Pegula—who share The Farmer's Dog's belief in doing the best we can for our dogs. The company also serves as the Official Pet Food of the Dallas Cowboys and the Dallas Cowboys Cheerleaders and is coming off its Emmy-nominated, USA Today Ad Meter®-winning Super Bowl commercial, Forever.

"We understand more than ever how much what we eat impacts our health and performance. NFL players live that every day, and people increasingly recognize the same is true for their dogs," said Jonathan Regev, CEO and Co-Founder of The Farmer's Dog. "We started The Farmer's Dog because for too long, feeding your dog meant choosing between different versions of the same ultra-processed food. This partnership gives us an incredible opportunity to show millions more people there's a better way. Everything we do is about helping dogs live healthier lives and giving people more time with them—more games, more Sundays, and more seasons together. Dogs have an incredible ability to make our lives better, and we're proud to partner with the NFL to celebrate that bond and what it means to have a dog by your side through all of it."

Fans can learn more about the partnership, watch the launch campaign, and follow along throughout the season at: thefarmersdog.com/nfl.

About The Farmer's Dog: For more than a decade, The Farmer's Dog has been setting a higher bar for pet care by providing freshly cooked and minimally processed meal plans designed to help dogs live longer, healthier lives. Our on-staff team of Board-Certified Veterinary Nutritionists®, PhD nutritionists, and veterinarians work to develop recipes packed with the nutrients dogs need, while avoiding the downsides of excess processing. Every meal is complete and balanced, made to human-grade safety standards, and delivered directly to customers' doors. Available at www.thefarmersdog.com and Walmart.com. Not available in Hawaii or Alaska.

Media Contact: [email protected]

SOURCE The Farmer's Dog

Share this article

C'est parti ! FOTON présente sa gamme complète de produits au salon IAA de Hanovre

PÉKIN, 9 septembre 2026 /PRNewswire/ -- Portée par la tendance mondiale à la décarbonisation, l'Europe, avec ses règles d'accès strictes et sa logistique bien développée, est devenue un terrain d'essai essentiel pour les véhicules utilitaires à énergie nouvelle à l'échelle mondiale. Dans le cadre de sa stratégie d'internationalisation, FOTON est allée au-delà de la simple exportation de produits individuels pour proposer des solutions complètes et adaptées au marché local, couvrant à la fois les produits, la technologie, la chaîne d'approvisionnement et les services après-vente.

Lors du salon IAA Transportation 2026 de Hanovre, FOTON tiendra un stand de plus de 1 000 mètres carrés dans le hall 21, sous le thème « EASY MOVE ». Elle présente sept véhicules complets et six composants clés développés en interne, adaptés aux principaux scénarios de transport européens, allant de la logistique longue distance à la collecte des déchets urbains et à la distribution en ville, en passant par les transports publics de passagers. Les produits exposés comprennent plusieurs modèles à énergie nouvelle, ainsi que des batteries haute performance, des essieux électriques, des systèmes de commande électroniques et des bornes de recharge d'une puissance de plusieurs mégawatts développés en interne, illustrant ainsi la capacité de FOTON à mener des activités de recherche et de développement indépendantes sur l'ensemble de la chaîne.

Titulaires des certifications WVTA et VECTO, les produits à énergie nouvelle de FOTON gagnent du terrain dans les différents pays européens. Son centre régional européen de distribution de pièces détachées, situé à Unna, en Allemagne, est désormais officiellement opérationnel afin d'améliorer l'efficacité du service après-vente au niveau local. S'appuyant sur 32 usines délocalisées à l'étranger, plus de 1 200 points de vente et plus de 1 500 points de service, FOTON a mis en place un système de service en boucle fermée couvrant la livraison des véhicules, l'approvisionnement en pièces détachées et l'entretien. De janvier à août 2026, le volume des exportations de FOTON a atteint 149 000 unités, soit une hausse de 44,3 % par rapport à la même période de l'année précédente.

Le 14 septembre, à l'occasion de la « Journée des médias » (de 8 h 40 à 9 h 10, heure locale en Allemagne, et diffusée en direct simultanément de 14 h 40 à 15 h 10 en Chine), FOTON fera trois annonces stratégiques majeures :

Dans un premier temps, l'entreprise dévoilera une nouvelle stratégie visant le marché européen, qui englobera le renouvellement de sa gamme de produits liés aux énergies nouvelles, la mise en place d'activités commerciales adaptées au contexte local et le développement d'un écosystème de services, tout en s'engageant fermement en faveur de la transition vers une économie à faibles émissions de carbone des véhicules utilitaires en Europe et de la fourniture de solutions de transport couvrant l'ensemble du cycle de vie.

Dans un second temps, l'entreprise célébrera une étape importante avec la livraison de son 13 millionième véhicule à l'échelle mondiale ; ce modèle fera d'abord son entrée sur le marché espagnol, marquant ainsi un moment clé dans le parcours de mondialisation de FOTON.

Dans un troisième temps, l'entreprise lancera le CAVAN BEACON — un poids lourd polyvalent fonctionnant à l'électricité et à l'hydrogène, conçu pour les longs trajets de plus de 300 km —, accompagné de 7 nouveaux véhicules électriques (NEV) et de 6 composants développés en interne (trois moteurs électriques, recharge d'un mégawatt), illustrant ainsi une indépendance technologique totale et une solution logistique chinoise zéro carbone.

Le stand restera ouvert aux concessionnaires, clients et médias du monde entier du 15 au 20 septembre. Les partenaires ZF, CATL et EVE Energy seront également présents pour mettre en avant la force de leur collaboration au sein de la chaîne d'approvisionnement.

Cette participation marque un nouveau départ pour FOTON en Europe et constitue une démonstration concrète de l'excellence de la fabrication intelligente chinoise sur la scène internationale.

Share this article

Zendure obtiene dos galardones en los Global Product Technology Innovation Awards 2026

-Zendure obtiene dos galardones en los Global Product Technology Innovation Awards 2026, con SolarFlow 4000 Mix Pro como ganador del Oro

En IFA 2026 celebrada en Berlín, el producto estrella de Zendure, el SolarFlow 4000 Mix Pro, se alzó con el Premio de Oro al Sistema de Almacenamiento de Energía Sostenible para el Hogar, mientras que Zendure recibió el Premio a la Marca de Soluciones de Energía Inteligente.

BERLIN, 9 de septiembre de 2026 /PRNewswire/ -- Zendure, pionero mundial en sistemas de gestión de energía doméstica enchufables (HEMS), anunció hoy que ha recibido dos galardones en los Global Product Technology Innovation Awards 2026. Su sistema insignia de almacenamiento de energía para el hogar, el SolarFlow 4000 Mix Pro, ganó el premio de Oro al Sistema de Almacenamiento de Energía Sostenible para el Hogar, mientras que Zendure fue nombrada ganadora del premio a la Marca de Soluciones de Energía Inteligente. Entregados durante la inauguración de IFA 2026 en Berlín, ambos premios reconocen el enfoque de Zendure en el sector del almacenamiento de energía limpia y su solución ligera, inteligente y de bajas emisiones de carbono para el suministro de energía en el hogar.

Premio de Oro al Sistema de Almacenamiento de Energía Sostenible para el Hogar: SolarFlow 4000 Mix Pro

El SolarFlow 4000 Mix Pro es un sistema de almacenamiento de energía doméstica enchufable todo en uno, bidireccional, de 4 kW de CA, impulsado por IA, que ofrece la capacidad y potencia de un sistema de almacenamiento doméstico en un formato enchufable. Una sola unidad ofrece una potencia que varía de 8 kWh a 50 kWh, y hasta 150 kWh al combinarse con el PowerHub de Zendure, que admite hasta 13 kW de energía solar total. Esto la hace ideal para viviendas grandes, bombas de calor y puntos de recarga de vehículos eléctricos. En combinación con paneles solares en el tejado, puede reducir los costes de electricidad del hogar hasta en un 91 %, lo que equivale a unos 2.560 € al año en un caso típico en Alemania.

Premio a la Marca de Soluciones Energéticas Inteligentes: Zendure

El premio Smart Energy Solutions Brand Award reconoce el liderazgo de Zendure en el ámbito de la energía inteligente para el hogar. El ecosistema SolarFlow de Zendure se adapta perfectamente, desde el almacenamiento plug-and-play hasta la gestión integral de la energía en el hogar. Su núcleo es Agentic HEMS, que utiliza datos de consumo, energía solar, clima y precios dinámicos para automatizar las decisiones energéticas, optimizar el uso de la energía durante los periodos de menor coste y reducir los gastos de electricidad del hogar. Este es un paso fundamental hacia la visión de la compañía de convertirse en el centro de referencia de la energía doméstica en la era de la IA.

Zendure presentará el SolarFlow 4000 Mix Pro y su ecosistema completo ZEN + Home en IFA 2026, pabellón 2.2, stand 124, del 4 al 8 de septiembre en Berlín.

Acerca de Zendure

Impulsados por nuestro propósito de acelerar un futuro sostenible, Zendure es un pionero mundial en sistemas HEMS enchufables. Con centros de I+D y operaciones en importantes centros tecnológicos como Silicon Valley y el Área de la Bahía, además de Japón y Alemania, nuestra visión es convertirnos en el centro de energía doméstica de la era de la IA. La misión de Zendure es brindar a cada hogar del mundo la máxima libertad en el control de su energía. Lo logramos a través del ecosistema SolarFlow, que combina almacenamiento modular, gestión inteligente de energía y entrada flexible de energía solar. SolarFlow se adapta sin problemas desde el almacenamiento plug-and-play y la modernización hasta la gestión integral de la energía en el hogar, maximizando el autoconsumo, reduciendo la dependencia de la red eléctrica y garantizando un respaldo confiable.

Share this article

JinkoSolar Schedules 2026 Annual General Meeting to be Held on October 21, 2026

SHANGRAO, China, Sept. 9, 2026 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. (the "Company," or "JinkoSolar") (NYSE: JKS), today announced that it will hold its 2026 annual general meeting on Wednesday, October 21, 2026 at 10:00 a.m. (Beijing time) at 10F, No.1, Lane 1466, Shenchang Road, Minhang District, Shanghai, China, for the following purposes:

- To re-elect Mr. Gang Chu as an independent director of the Company;

- To re-elect Mr. Steven Markscheid as an independent director of the Company;

- To ratify the appointment of PricewaterhouseCoopers Zhong Tian LLP as auditors of the Company for the fiscal year of 2026;

- To authorize the directors of the Company to determine the remuneration of the Company's auditors;

- To change the English name of the Company from "JinkoSolar Holding Co., Ltd." to "Jinko Holdings Limited";

- To adopt "晶科控股有限公司" as the dual foreign name of the Company;

- To authorize each of the directors of the Company to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit;

- To receive and consider the audited financial statements and the report of the auditors for the year ended December 31, 2025, and the report of the board of directors; and

- To act upon such other matters as may properly come before our annual general meeting or any adjournment or postponement thereof.

Only shareholders of record at the close of business on September 21, 2026 (New York time) are entitled to receive notice of and to vote at the Company's annual general meeting or any adjournment or postponement thereof.

The notice of the Company's annual general meeting and the Company's 2025 Annual Report, containing the complete audited financial statements and the report of auditors for the year ended December 31, 2025, together with the report of the board of directors, are available on the Investor Relations Section of the Company's website at www.jinkosolar.com.

The Company will provide to all shareholders, upon request, a hard copy of the Company's 2025 Annual Report and the report of the board of directors free of charge.

About JinkoSolar Holding Co., Ltd.

JinkoSolar (NYSE: JKS) is a holding company combining clean energy industrial operations and strategic investment in emerging technologies. Its industrial foundation is a controlling interest in Jinko Solar Co., Ltd. (SSE: 688223), a global leader in clean energy technology. The Company makes disciplined strategic investments in renewable energy, advanced materials, artificial intelligence, commercial space and other frontier technologies, drawing on its industrial experience and its ability to identify emerging technologies and bring them to commercial scale.

Through Jinko Solar Co., Ltd., the Company distributes its solar products and sells its solutions and services to a diversified international utility, commercial and residential customer base in China, the United States, Japan, Germany, the United Kingdom, Chile, South Africa, India, Mexico, Brazil, the United Arab Emirates, Italy, Spain, France, Belgium, Netherlands, Poland, Austria, Switzerland, Greece and other countries and regions.

JinkoSolar has over 10 production facilities globally, over 20 overseas subsidiaries in Japan, South Korea, Vietnam, India, Turkey, Germany, Italy, Switzerland, the United States, Mexico, and other countries, and a global sales network with sales teams in China, the United States, Canada, Brazil, Chile, Mexico, Italy, Germany, Turkey, Spain, Japan, the United Arab Emirates, Netherlands, Vietnam and India, as of June 30, 2026.

To find out more, please see: www.jinkosolar.com

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's operations and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in JinkoSolar's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. Except as required by law, the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:

In China:

Ms. Stella Wang

JinkoSolar Holding Co., Ltd.

Tel: +86 21-5180-8777 ext.7806

Email: [email protected]

Mr. Christian Arnell

Christensen

Tel: +852 2117 0861

Email: [email protected]

In the U.S.:

Email: [email protected]

SOURCE JinkoSolar Holding Co., Ltd.

Share this article

All-new LinkRunner 100G - professional-grade performance and precision tool network engineers need to troubleshoot and upgrade critical 100G fiber links.

COLORADO SPRINGS, Colo., Sept. 9, 2026 /PRNewswire/ -- NetAlly today announced LinkRunner® 100G, a handheld tester built to validate and troubleshoot high-speed fiber links increasingly moving beyond data centers and into enterprise networks. With the press of a single button, LinkRunner 100G AutoTest tells a network technician whether a 100G link is healthy — and if it isn't, exactly what's wrong. At $8,999 plus an AllyCare Pro subscription, LinkRunner 100G delivers the professional-grade diagnostics network engineers expect from a 100G tester at a price built for enterprise IT.

"AI is driving a networking super-cycle, pushing higher-speed networks beyond the data center and into the enterprise," said Jeff O'Mara, CEO of NetAlly. "Until today, the tools to support those networks were expensive and highly specialized for big telco providers. Enterprise IT is different. We built LinkRunner 100G to give enterprise network professionals the tool they need to deploy, fix, and upgrade these networks."

As 25G, 40G, 50G, and 100G networks become more common in enterprise environments, IT teams are being asked to manage fiber networks that operate differently from the lower-speed connections they have traditionally supported. Troubleshooting networks running on twisted-pair copper up to 10G has been eased by rich automation specified by IEEE standards for auto-negotiation of speed, power, and polarity. None of this automation exists for 100G networks, resulting in brittle, hard-coded configurations. Vendors further complicate the space with proprietary, complex transceivers that modify encodings and bit rates to gain advantages in fiber efficiency and bandwidth.

LinkRunner 100G is designed specifically for these new challenges faced by network support teams, allowing technicians to run a full diagnostic at the push of a button, with no specialized fiber training required.

With LinkRunner 100G, network pros solve problems on 100G networks with simple, automated steps:

- Catch configuration mismatches that can leave a Quad Small Form-factor Pluggable 28 (QSFP28) port down, even when nothing is actually broken. QSFP Insights identifies the transceiver, fiber type, speed, and Forward Error Correction (FEC) settings, helping uncover mismatches that can be difficult to spot through the switch alone.

- Pinpoint the problem to make the fix, rather than guessing. NetAlly's EZ Wired app validates the link speed, FEC, interfaces, network services, and application connectivity as well as transceiver operation. Since each parameter must be set by the user on the switches, knowing the exact set of parameters provides the network pro with the recipe for success.

- See where the traffic is actually getting stuck, rather than assuming the problem is the link being tested. Path Analysis traces the network path from the tester to its destination, hop by hop, revealing when a slowdown originates elsewhere, such as an overloaded switch several hops away.

- Identify when a 100G link is trending in a bad direction and may be close to failing – before it does. Forward Error Correction (FEC), which enables higher-speed fiber connections by correcting damaged bits, can mask a degrading link while the network continues to operate. AutoTest catches failures before your users do and captures the information in Link-Live.

- Verify that the network performs as specified and prove that you are getting the performance you paid for. Use Performance Test to validate newly deployed infrastructure, troubleshoot existing networks, and confirm expected throughput.

"Higher-speed fiber is quickly becoming part of the enterprise network, and IT teams need to be ready for it," O'Mara said. "If you're responsible for links above 10G, LinkRunner 100G belongs in your toolkit."

LinkRunner 100G is handheld and battery-powered, so technicians can take it on any call, not just escalations. Results are translated into plain-language answers rather than error codes and can be uploaded to Link-Live, NetAlly's collaboration and reporting platform, so a technician can share a full report instead of a screenshot.

Pricing and Availability

LinkRunner 100G is now available for $8,999, plus an AllyCare Pro subscription, through NetAlly's network of authorized resellers. For full details, visit www.netally.com.

About NetAlly

Since introducing the industry's first handheld network analyzer in 1993, NetAlly has helped network professionals deploy, manage, maintain, and secure today's complex wired and wireless networks. Visit www.netally.com or contact 1-844-878-2559.

SOURCE NetAlly

Share this article

Multi-Touch Campaign Targets Businesses Migrating From QuickBooks and Legacy Systems

MISSION VIEJO, Calif., Sept. 9, 2026 /PRNewswire/ -- ERPVAR today announced a collaborative partnership agreement with Crawford Software to execute comprehensive ERP software lead generation activities. The alliance focuses on capturing high-intent opportunities within discrete manufacturing and complex distribution sectors.

Discover how modern ERP solutions can optimize your manufacturing or distribution operations. Join our next live migration webinar by signing up at ERPVAR Events or contact us for more information.

The partnership addresses a critical market need for Crawford Software: the ability to identify and engage mid-market organizations preparing to move away from legacy systems such as QuickBooks and various legacy platforms. By leveraging ERPVAR's established database and multi-touch marketing infrastructure, Crawford Software aims to streamline the sales cycle from initial buyer intent to booked meetings.

Strategic Deliverables

- Sales Prospecting Execution: Crawford gains dedicated access to the ERPVAR HubSpot portal, enabling targeted outbound sequences for migration opportunities

- Lead Qualification: Real-time buyer intent data is paired with assigned Business Development Representative (BDR) assistance to qualify prospects and schedule sales appointments directly.

- Content and AEO: The strategy includes four original blog posts per month and structured HubSpot Topic Clusters to improve rankings across search and AI generative engines.

- Migration Webinars: One targeted migration webinar campaign per quarter will engage active migration prospects within the ERPVAR database.

Operational efficiency remains a core component of this collaboration. Crawford Software will utilize eight custom sales sequence templates per quarter, tailored by industry and specific trigger events. This turnkey infrastructure allows the sales team to focus on closing deals rather than building marketing assets from scratch. Data integration options for Salesforce further ensure a frictionless workflow between the two organizations, providing a direct pipeline to companies evaluating modern ERP solutions .

"This strategic partnership between ERPVAR and Crawford Software is engineered to drive a 30% increase in qualified sales pipeline for mid-market companies navigating complex ERP migrations. By combining our specialized digital marketing infrastructure, including 4 original blog posts per month and targeted migration webinar campaigns, we are positioning Crawford Software to capture significant market share in the discrete manufacturing and distribution sectors," said Adrian Montgomery, Partner at ERPVAR.com.

About ERPVAR ERPVAR.com is a leading online resource and lead-generation portal dedicated to connecting businesses with top-tier Enterprise Resource Planning (ERP) software vendors and expert implementation partners. Specializing in helping growing organizations navigate complex digital transformations, ERPVAR combines AI engine optimization (AEO), targeted search engine marketing, and multi-touch lead nurturing campaigns to drive high-intent sales opportunities for its technology partners. Through strategic buyer intent tracking, industry-tailored sequence creation, and joint educational webinars, ERPVAR empowers mid-market manufacturers, distributors, and migrating enterprise clients to find the ideal ERP software solution for their operational needs. To learn more, visit www.erpvar.com.

About Crawford Software

Crawford Software provides ERP consulting, support, and solutions tailored to manufacturers and distributors across New England and the Tri-State area. With their expertise, Crawford Software helps companies streamline operations, improve visibility, and grow their business efficiently.

SOURCE ERPVAR

Share this article

An estimated 7 billion male chicks are killed worldwide each year, as alternatives to chick culling become increasingly available

LOS ANGELES, Sept. 9, 2026 /PRNewswire/ -- For decades, chick culling, the routine killing of newly hatched male chicks because they cannot lay eggs and are not considered profitable by the egg industry, has been treated as an unavoidable part of egg production. An estimated 7 billion newly hatched male chicks, approximately 200 every second, are killed worldwide each year.

But as technologies and other alternatives become increasingly available, that is beginning to change. In-ovo sexing technology can identify the sex of an embryo before hatching, providing one pathway for eliminating the need to kill male chicks after they are born. The technology is already being used commercially, and countries and companies are beginning to move away from chick culling. Yet despite these advances, billions of newly hatched male chicks continue to be killed each year, raising questions about why the practice persists when alternatives are available.

A new Mercy For Animals investigation provides a firsthand look at chick culling inside a commercial hatchery.

The investigation documents newly hatched male chicks being forcibly separated from female chicks and killed shortly after hatching. Depending on the facility, common methods of chick culling include maceration and gassing. The investigation also documented deformed or unsold female chicks being discarded through the same process.

The findings come as chick culling begins to change elsewhere. Germany and France have banned the practice, while in-ovo sexing technology has reached commercial use in markets, including the United States and Brazil. Canada has also seen the development of technology capable of determining sex as early as day four of incubation.

"Every year, billions of chicks are killed simply because they are born male," said Arash Yomtobian, president and CEO of Mercy For Animals. "The technology to end this practice already exists. There is no justification for allowing it to continue."

"Given the serious ethical concerns created by traditional chick culling, it is very promising to see the advancements in in-ovo sexing technologies," said Andrew Knight, veterinary professor of animal welfare. "MRI with AI approaches have achieved more than 99% accuracy, processing times under one second, and costs that average only one cent per table egg. More importantly, these technologies are able to identify male embryos prior to day 13, meaning that they are very unlikely to experience any pain. With hatcheries quickly adopting the technology in Europe and now the United States, we can eliminate chick culling in the near future."

"Most people have never heard of chick culling, despite the enormous scale of the practice," Yomtobian said. "Mercy For Animals wants to change that. By helping more people understand what is happening and what alternatives exist, we can build the public support needed to move the industry toward ending chick culling."

Through Crack the System, a new global campaign, Mercy For Animals is calling for an end to chick culling and supports policies and industry action that move egg production away from the routine killing of newly hatched male chicks.

For more information or to schedule an interview, contact Ronnika A. McFall at [email protected].

Mercy For Animals is a leading international nonprofit working to end industrial animal agriculture by constructing a just and sustainable food system. Active in Brazil, Canada, India, Mexico, Southeast Asia, and the United States, the organization has conducted over 100 investigations of factory farms and slaughterhouses, influenced over 500 corporate policies, and helped pass historic legislation to ban cages for farmed animals. Learn more at MercyForAnimals.org.

SOURCE Mercy For Animals

Share this article